QTTB (Q32 Bio Inc) Market Value to Book Value Ratio
The development of specific immune agents has reached late-stage trials, and the current liquidity reserve stands at 1.98, ensuring financial stability. Q32 Bio Inc. (QTTB) is developing biologics to correct autoimmune processes, competing with global behemoths through strong clinical results. This chart of the Q32 Bio Inc. (QTTB) asset value complements data on complement system therapy targeting patients with severe inflammation and insurance reimbursement.
%3A%20Market%20Capitalization%20to%20Net%20Assets&width=1200&height=400&colorIndex=0&v=mvrk6wqv.ssk-7as46ww&start=20220704&end=20261028&filename=GURU_Markets_-_QTTB_-_Q32-Bio-Inc._-_Market-Capitalization-to-Net-Assets "QTTB Q32 Bio Market Capitalization to Book Value Ratio (03/27/2024 - 10/28/2026) | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for Q32 Bio Inc. (QTTB)
- price and consensus price forecast:
- market capitalization data:
- book capitalization data:
- debt and liquidity data:
Initial company analysis:Q32 Bio Inc - QTTB
This indicator compares the market value of Q32 Bio Inc. (QTTB) to its net assets, depending on operational efficiency. The ratio determines the gap between the exchange valuation and book capital, reflecting market expectations for returns. Investments in the environmental modernization of laboratories and ESG filtration directly impact the balance sheet value. Analyzing the market-to-book multiple allows for the timely identification of an overbought asset.
Main competitors
argenx SE (ARGX) - Market Capitalization to Book Value Ratio|BNTX (biontech.de) - Market Value to Book Value Ratio|Market Value to Book Value Ratio abivax.com ABVX|Market Capitalization to Net Assets ADMA Biologics Inc|Protagonist Therapeutics Inc (PTGX) - Market Capitalization to Book Value Ratio|Market Value to Book Value Immunovant Therapeutics (IMVT)|Market Capitalization to Book Value Ratio KNSA (Kiniksa Pharmaceuticals)|grifols.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Adaptive Biotechnologies Corporation (ADPT)|CLDX: Market Value to Book Value|AUPH (Aurinia Pharma) - Market Value to Book Value Ratio|BioCryst Corp (BCRX) - Market Cap to Net Assets Ratio|VERA (Vera Therapeutics, Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio dianthustx.com (DNTH)|Pharvaris (PHVS) - Market Cap to Net Assets Ratio|Market Value to Book Value AbCellera Biologics (ABCL)|Market Capitalization to Book Value Ratio TRML|Precigen Corp - Market Capitalization to Book Value|PHAR: Market Value to Book Value Ratio|NKTR: Market Cap to Net Assets Ratio|UPB (Upstream Bio) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Zenas Bio|IMNM (Immunome Corp) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio GOSS|Market Value to Book Value Ratio KalVista Pharmaceuticals KALV|Capitalization to Book Value Ratio septerna.com (SEPN)|PVLA: Market Capitalization to Book Value Ratio|Savara Inc - Market-to-Book Ratio|Market Value to Book Value Ratio RIGL|AnaptysBio Inc. (ANAB) - Market Value to Equity Ratio|Astria Therapeutics (ATXS) - Market Cap to Net Assets Ratio|Market Value to Book Value Ratio engene.com|RAPT - Market Cap to Net Assets Ratio|Market Value to Book Value Aerovate|Market Capitalization to Book Value Ratio Aclaris (ACRS)|Market Value to Book Value Ratio Kyverna Therapeutics, Inc (KYTX)|Market Capitalization to Book Value Ratio TLSA|cabalettabio.com - Market Capitalization to Book Value|VTYX (Ventyx Biosciences, Inc.) - Market Value to Book Value Ratio|Theratechnologies, Inc. (THTX) - Market-to-Book Ratio|Market Cap to Net Assets Ratio Avalo Therapeutics Inc. AVTX|Eledon Pharmaceuticals, Inc (ELDN) - Market Value to Book Value|AGEN: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value CLYM|Market Value to Book Value Ratio Zura Bio ZURA|Capitalization to Book Value Ratio aTyr Pharma Inc (ATYR)|Adagene Inc. - Market Capitalization to Book Value Ratio|IMA - Market Cap to Net Assets Ratio|Market Cap to Net Assets Ratio STTK (Shattuck Therapeutics)|EQ: Market Capitalization to Book Value|Market Value to Book Value Ratio CNTB (connectbiopharm.com)|Market Value to Equity Ratio Immunic|Atara Biotherapeutics, Inc. (ATRA) - Market Cap to Net Assets Ratio|Market Cap to Book Value Multiple InflaRx GmbH (IFRX)|Market Cap to Net Assets Ratio X4 Pharmaceuticals|Market Cap to Book Value Multiple adicetbio.com (ACET)|Market Capitalization to Book Value Ratio Celularity CELU|INmune Bio Inc - Market Value to Book Value Ratio|Market Value to Book Value Ratio Barinthus Bio|KZR - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio SAB Biotherapeutics SABS|akaritx.com (AKTX) - Market Value to Book Value|ENLV (Enlivex Therapeutics Ltd) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio GOVX|Edesa (EDSA) - Market Value to Book Value Ratio|Market Value to Book Value IBIO (iBio Corporation)|Carisma Therapeutics Inc. - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio xtlbio.com XTLB|Bolt Bio - Market Capitalization to Book Value Ratio|HCW Biologics Inc. (HCWB) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio aptevotherapeutics.com APVO|aimimmuno.com (AIM) - Market Value to Book Value|ADTX: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value GRI|Market Value to Book Value Ratio XRTX (XORTX Therapeutics)|Market Cap to Net Assets Ratio HIND (Vyome Holdings Inc.)|Revelation Bio - Market Value to Book Value Ratio|INDP - Market Cap to Net Assets Ratio|Scinai Immunotherapeutics - Market Cap to Net Assets Ratio|CALI: Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio affimed.com|Allakos (ALLK) - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio HOOK (HOOKIPA Pharma, Inc.)|Market-to-Book Ratio IGMS|ITOS: Market Value to Book Value Ratio|Market Value to Equity Ratio oceanbiomedical.com OCEA|Market Cap to Net Assets Ratio TC BioPharm TCBP|THRD - Market Value to Book Value Ratio